Immunotherapy, including immune checkpoint inhibitors, adoptive cell therapy, cancer
vaccines, and other modalities, represents a significant advancement in cancer treatment …

Breast cancer, characterized by unique epidemiological patterns and significant
heterogeneity, remains one of the leading causes of malignancy-related deaths in women …

Immune checkpoint inhibitors (ICIs) offer promise in breaking through the treatment and
survival dilemma of triple‐negative breast cancer (TNBC), yet only immunomodulatory …

Background Invasive micropapillary carcinoma (IMPC) is a rare subtype of breast cancer. Its
epidemiological features, treatment principles, and prognostic factors remain controversial …

The multi-kinase inhibitor sorafenib has shown potential to inhibit tumor cell growth and intra-
tumoral angiogenesis by targeting several kinases, including VEGFR2 and RAF. Abnormal …

Abstract Background Breast Cancer (BC) can be classified, due to its heterogeneity, into
multiple subtypes that differ for prognosis and clinical management. Notably, triple negative …

Introduction Altered epigenetic reprogramming enables breast cancer cells to adapt to
hypoxic stress. Hypoxic microenvironment can alter immune cell infiltration and function …

Simple Summary Breast cancer continues to represent a leading cause of death among
women globally. Recent studies have shown a growing link between breast cancer and the …

Background: Representing 15–20% of all breast cancer cases, triple negative breast cancer
(TNBC) is diagnosed more frequently in reproductive-age women and exhibits higher rates …

We recently delved into the enlightening article by Zheng and colleagues in the International
Journal of Surgery [1], which evaluated the efficacy and safety of camrelizumab, an IgG4-k …